Novel cancer antigen peptide and the use thereof
AssigneeToray Industries, Inc.
InventorFumiyoshi Okano
Life of this patent
Estimating the term…
Abstract
Novel peptides useful as a therapeutic and/or prophylactic agent of cancers, as well as medical uses thereof, are described. Each of these peptides have a consecutive amino acid sequence within a specific region of YKL-40 antigen expressing on the cell surface of brain tumor cells, that is, within the region aa10-19, aa49-61, aa74-83, aa96-117, aa152-161, aa177-185, aa202-211, aa246-261 or aa326-354, which peptide has an immunity-inducing activity. These peptides are useful for therapy and/or prevention of cancers when administered to a living body, and are useful for inducing T cells which exert cytotoxic activity against cancer cells when used to stimulate the T cells in vitro.
Claims27
A peptide having not less than 7 consecutive amino acids in the region of aa10-19, aa49-61, aa74-83, aa96-117, aa152-161, aa177-185, aa202-211, aa246-261 or aa326-354 in SEQ ID NO:2 in SEQUENCE LISTING, which peptide has an immunity-inducing activity, or a peptide having 7 to 30 amino acid residues having an identity of not less than 80% to any one of said peptides, which peptide has an immunity-inducing activity, or a peptide having 8 to 31 amino acid residues, comprising any one of said peptides as a partial sequence thereof, which peptide has an immunity-inducing activity.
A cancer-specific immunity-inducing agent comprising as an effective ingredient a protein having the amino acid sequence shown in SEQ ID NO:2 or a protein having an immunity-inducing activity, which protein has an amino acid sequence with an identity of not less than 80% to said amino acid sequence shown in SEQ ID NO:2.
Dependencies are inferred from the claim text.